European CHMP recommends approval of enzalutamide (Xtandi®) for prostate cancer
European Medicines Agency - EMA
European Medicines Agency
26 April 2013
The EMA’s CHMP has adopted a positive opinion recommending approval of enzalutamide (Xtandi®) for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.